These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9638171

  • 1. [Use of filgrastim, granulocyte colony stimulating factor (G-CSF), in radiotherapy to reduce drop-outs because of radiogenic leukopenia].
    Gava A, Bertossi L, Ferrarese F, Coghetto F, Marazzato G, Andrulli AD, Zorat PL.
    Radiol Med; 1998 Mar; 95(3):232-6. PubMed ID: 9638171
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM.
    Cancer; 2002 Jan 15; 94(2):285-91. PubMed ID: 11900213
    [Abstract] [Full Text] [Related]

  • 3. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 4. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov 15; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 5. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May 15; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 6. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct 15; 15(85):189-91. PubMed ID: 17128529
    [Abstract] [Full Text] [Related]

  • 7. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
    Alvarado Ibarra ML, Borbolla Escoboza JR, López-Hernández MA, González-Avante CM, FloresChapa JD, Trueba Christy E, Anaya Cuellar I.
    Rev Invest Clin; 1999 Oct 15; 51(2):77-80. PubMed ID: 10410585
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
    Basser RL, To LB, Begley CG, Juttner CA, Maher DW, Szer J, Cebon J, Collins JP, Russell I, Olver I.
    Clin Cancer Res; 1995 Jul 15; 1(7):715-21. PubMed ID: 9816037
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC, Bernard JL.
    Anticancer Drugs; 2007 Mar 15; 18(3):277-81. PubMed ID: 17264759
    [Abstract] [Full Text] [Related]

  • 10. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.
    Korzenik JR, Dieckgraefe BK.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):391-400. PubMed ID: 15709989
    [Abstract] [Full Text] [Related]

  • 11. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
    Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J.
    Cancer; 2004 Jun 15; 100(12):2592-7. PubMed ID: 15197801
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone C, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F.
    J Clin Oncol; 2005 Oct 01; 23(28):6908-18. PubMed ID: 16129844
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S, Arpaci F, Turan M, Solchaga L, Cetin T, Ozturk M, Ozet A, Komurcu S, Ozturk B.
    Am J Hematol; 2008 Aug 01; 83(8):644-8. PubMed ID: 18508321
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS.
    Eur J Cancer; 2009 Mar 01; 45(4):608-17. PubMed ID: 19110415
    [Abstract] [Full Text] [Related]

  • 18. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.
    Gynecol Oncol; 2005 Jan 01; 96(1):198-203. PubMed ID: 15589601
    [Abstract] [Full Text] [Related]

  • 19. [Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].
    Korman DB, Boronovskaia LE, Maslova IA, Andreeva EV, Seregina GV.
    Vopr Onkol; 2008 Jan 01; 54(5):639-42. PubMed ID: 19069482
    [Abstract] [Full Text] [Related]

  • 20. Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis.
    Wickramanayake PD, Scheid C, Josting A, Katay I, Schulz A, Diehl V.
    Eur J Med Res; 1995 Dec 18; 1(3):153-6. PubMed ID: 9445760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.